Since decades selection of antibody producing hybridoma cells has been performed by limited dilution and numerous ELISA screenings in order to find suitable antibody-producing cells. These processes are very laborious, time-consuming and expensive. This dilemma motivated us to develop a new selection technology. We developed selma: selma is based on transgenic myeloma cell lines expressing an artificial surface marker. These enable us to link the antigen-specific antibody and the secreting hybridoma cell. Moreover, the system allows a flexible screening for wanted isotypes and wanted or non-wanted cross-reactivities. In combination with our viral immunization system the process of reliable antibody generation and validation is hence finished within less than 3 months.